Dibenzosuberone

CAS No. 1210-35-1

Dibenzosuberone ( —— )

Catalog No. M10785 CAS No. 1210-35-1

Pharmaceutical intermediates for the synthesis of drug amitriptyline.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 45 In Stock
50MG 53 In Stock
100MG 81 In Stock
200MG 147 In Stock
500MG 211 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dibenzosuberone
  • Note
    Research use only, not for human use.
  • Brief Description
    Pharmaceutical intermediates for the synthesis of drug amitriptyline.
  • Description
    Pharmaceutical intermediates for the synthesis of drug amitriptyline.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1210-35-1
  • Formula Weight
    208.26
  • Molecular Formula
    C15H12O
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C1C2=CC=CC=C2CCC2=CC=CC=C12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Merkas S, et al. Molecules. 2005 Dec 31;10(12):1429-37.
molnova catalog
related products
  • Fmoc-NH-PEG12-CH2CH2...

    Fmoc-NH-PEG12-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • Rebaudioside D

    Rebaudioside D is a potential sweetener. Rebaudioside D shows similar stability when exposed to simulate stomach and small intestine fluids with susceptibility to hydrolytic degradation by enteric bacteria collected from the cecum.

  • 3-Hydroxybakuchiol

    3-Hydroxybakuchiol exerts cytotoxic and anti-proliferative effects on the TA3/Ha mouse mammary adenocarcinoma cell line and induces a decrease in the mitochondrial transmembrane potential, the activation of caspase-3, the opening of the mitochondrial permeability transport pore (MPTP) and nuclear DNA fragmentation.3-Hydroxybakuchiol has antitumor activity resulting from interactions with the ETC, a system that is already deficient in cancer cells.